Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Non-Randomized Phase 2 Study With Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma

NCT03127020 is registered in ClinicalTrials.gov with PIQUR Therapeutics AG as lead sponsor.

NCT NCT03127020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03127020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Non-Randomized Phase 2 Study With Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma
Lead sponsor
PIQUR Therapeutics AG
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
Not reported
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin lymphoma